Skip to main content
. 2012 Dec 19;7(12):e51681. doi: 10.1371/journal.pone.0051681

Figure 1. Immunohistochemistry for CD20 and FOXP3 at study entry and at first response evaluation (1–2 months after finishing treatment).

Figure 1

Gastric biopsies samples from 4 gastric MALT lymphoma patients treated with different schedules. HP: erradication therapy alone; RQ: Rituximab+CHOP; RF: Rituximab+Fludarabine; RB: Rituximab+Bendamustine.